Drug Treatment of Parkinson's Disease
BMJ 310:575-579, Quinn,N., 1995
Olanzapine in the Treatment of Dopaminomimetic Psychosis in Patients with Parkinson's Disease
Neurol 47:1085-1087, Wolters,W.Ch.,et al, 1992
Psychotic Reactions During Treatment of Pituitary Tumours with Dopamine Agonists
BMJ 289:1101-1103, Turner,T.H.,et al, 1984
Clinical Features of Dopamine Agonist Withdrawal Syndrome in a Movement Disorders Clinic
JNNP 84:130-135, Pondal, M.,et al, 2013
Fourteen-Year Final Report of the Randomized PDRG-UK Trial Comparing Three Treatments in PD
Neurol 71:474-480.470, Katzenschlager,R.,et al., 2008
Acromegaly
NEJM 355:2558-2573, Melmed,S., 2006
Psychosis Related to Ropinirole
Am J Psychiatry 163:546-547, Perea,E.,et al, 2006
Ten-year Follow-up of Three Different Initial Treatments in De-novo PD
Neurol 57:1687-1694, Lees,A.J.,et al, 2001
Acute Orhtostatic Hypotension When Starting Dopamine Agonists in Parkinson's Disease
Arch Neurol 57:1461-1463, Kujawa,K.,et al, 2000
A 3-Year Randomized Trial of Ropinirole and Bromocriptine in Early Parkinson's Disease
Neurol 53:364-370, Korczyn,A.D.,et al, 1999
The Efficacy of (+) -4-Propyl-9-Hydroxynaphthoxazine as Adjunctive Therapy in Parkinson's Disease
JNNP 52:732-735, Weiner,W.J.,et al, 1989
Treatment of Advanced Parkinson Disease With Pergolide
Neurol 31:675-682, Lieberman,A.,et al, 1981
Drug Therapy, Bromocriptine
NEJM 301:873-878, Parkes,D., 1979